Researchers Awarded $28M for Illuminating Druggable Genome NIH Grants
Bryan L. Roth, MD, PhD, the Michael Hooker Distinguished Professor of Protein Therapeutics and Translational Proteomics in the Department of Pharmacology at the UNC School of Medicine, and Gary Johnson, PhD, the Kenan Distinguished Professor of Pharmacology and former chair, were each awarded NIH Illuminating the Druggable Genome Awards from the National Institutes of Health, totaling $28 million over six years. Investigators from the University of California at San Francisco received the third of these prestigious grants. Both are members of the UNC Lineberger Comprehensive Cancer Center.
Even though the DNA sequence of the human genome has been defined for more than 20 years, the function of many genes are still poorly defined. Scientists don’t understand the function of many proteins encoded in our DNA. In an attempt to address this deficiency, the NIH established an initiative called “Illuminating the Druggable Genome” or IDG to use experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.
In many human diseases, these three families are important therapeutic targets for FDA-approved drugs. The IDG consortium, established in 2014, wanted to know if understudied members of these three gene families were important in human disease. The goal was to have researchers use scalable technology platforms to characterize functions of understudied ion channels, GPCRs, and protein kinases. The NIH wanted this initiative to feature high-throughput technologies, not the “one gene at a time” approach. Researchers would define molecular, cellular, and/or physiological roles and potentially identify new tractable drug targets within the understudied proteins.
The NIH nationally advertised a new funding opportunity for Data and Resource Generation Centers for Illuminating the Druggable Genome. Three six-year grants would be funded: one each for ion channels, GPCRs and protein kinases.
Roth, who is director of the NIMH Psychoactive Drug Screening Program, is the principal investigator for the GPCR research effort. Johnson leads the protein kinase group. The awards include collaborators at UNC and other universities. Four labs at UCSF lead the ion channel group. The UNC awards are for $14 million each.
This article has been republished from materials provided by UNC Lineberger. Note: material may have been edited for length and content. For further information, please contact the cited source.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019